Trodelvy (Sacituzumab govitecan)

sacituzumab govitecan 180 mg injection, 1 vial · INJECTION · PBS code 12966K

STREAMLINED

What it costs

AU$1484.59 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2022-05-01.
• Repeats: 7.
• PBS program: IP.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Unresectable locally advanced or metastatic triple-negative breast cancer

Initial treatment

Patient must have progressive disease following two or more prior systemic therapies, at least one of them in the locally advanced or metastatic setting; AND

The condition must be inoperable; AND

Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score no higher than 1 prior to treatment initiation; AND

The treatment must be the sole PBS-subsidised therapy for this PBS indication.

Sponsor: Gilead Sciences Pty Limited ABN 71 072 611 708

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.